Vonoprazan Fumarate CAS 1260141-27-2
Product Name: Vonoprazan Fumarate
CAS No.: 1260141-27-2
Product Type: Pharmaceutical API
Pharmaceutical Class: Potassium-Competitive Acid Blocker (P-CAB)
Grade: Pharmaceutical Grade
Application: Gastrointestinal Pharmaceutical Products
Molecular Formula: C21H20FN3O6S
Sample: Available upon request
Packaging: Available according to requirements
Vonoprazan Fumarate CAS 1260141-27-2 is a pharmaceutical active ingredient and the fumarate salt form of vonoprazan. It belongs to the potassium-competitive acid blocker (P-CAB) class and is used in pharmaceutical products involving gastric acid suppression. Xi’an Deli Biochemical Industry Co., Ltd. provides Vonoprazan Fumarate API for pharmaceutical development, formulation research, analytical evaluation, supplier qualification, and commercial manufacturing.
With more than 27 years of experience in the pharmaceutical and biochemical industry, Xi’an Deli specializes in the development and supply of pharmaceutical APIs and excipients for international pharmaceutical customers.
Product Name: Vonoprazan Fumarate
CAS No.: 1260141-27-2
Alternative CAS No.: 881681-01-2
Development Code: TAK-438
Product Type: Active Pharmaceutical Ingredient (API)
Pharmaceutical Class: Potassium-Competitive Acid Blocker (P-CAB)
Grade: Pharmaceutical Grade
Molecular Formula: C21H20FN3O6S
Molecular Weight: 461.46 g/mol
Application: Pharmaceutical Use
Product Form: Please contact us for detailed product information
Sample: Available upon request
Packaging: Available according to quantity and customer requirements
Manufacturer: Xi’an Deli Biochemical Industry Co., Ltd.
Vonoprazan Fumarate is the fumarate salt form of vonoprazan and belongs to the potassium-competitive acid blocker (P-CAB) class. It is an important pharmaceutical API for products designed to suppress gastric acid secretion.
Vonoprazan acts on the gastric H+/K+-ATPase proton pump, which is responsible for the final step of gastric acid secretion by gastric parietal cells. By inhibiting this proton pump, vonoprazan reduces gastric acid secretion.
Compared with conventional proton pump inhibitors (PPIs), vonoprazan uses a different mechanism of gastric acid suppression. It competitively inhibits potassium binding at the gastric H+/K+-ATPase and therefore provides a distinct pharmacological approach to controlling gastric acid production.
The pharmacological characteristics of vonoprazan make Vonoprazan Fumarate API relevant to pharmaceutical development projects involving acid-related gastrointestinal conditions and combination therapies.
Vonoprazan belongs to the potassium-competitive acid blocker (P-CAB) class. Its primary pharmacological action is related to inhibition of the gastric H+/K+-ATPase proton pump.
The gastric proton pump is located in gastric parietal cells and plays a central role in the secretion of hydrochloric acid into the stomach. Vonoprazan competitively inhibits potassium binding to the proton pump, reducing its ability to secrete hydrogen ions.
Vonoprazan → H+/K+-ATPase inhibition → Reduced gastric acid secretion
This mechanism differentiates vonoprazan from conventional acid-suppressing APIs and is one of the key pharmaceutical characteristics of Vonoprazan Fumarate.
Vonoprazan Fumarate CAS 1260141-27-2 is primarily used as an active pharmaceutical ingredient in products associated with gastric acid suppression. Its mechanism of action makes it relevant to several gastrointestinal pharmaceutical applications.
Vonoprazan has been developed for pharmaceutical products used in the treatment of gastroesophageal reflux disease (GERD) and other acid-related conditions. By suppressing gastric acid secretion, vonoprazan can be used in pharmaceutical formulations intended to manage acid-mediated gastrointestinal conditions.
Erosive esophagitis is associated with exposure of the esophageal mucosa to gastric acid. Vonoprazan-based pharmaceutical products can be used in this therapeutic area because of the strong gastric acid suppression provided by its P-CAB mechanism.
Gastric acid plays an important role in several gastrointestinal conditions. Vonoprazan Fumarate API can therefore be evaluated in pharmaceutical development projects where controlled suppression of gastric acid secretion is required.
Vonoprazan-based pharmaceutical products are also associated with acid-related gastric and duodenal ulcer treatment. Pharmaceutical companies developing products for these therapeutic areas may evaluate Vonoprazan Fumarate as an API source.
An important pharmaceutical application of vonoprazan is its use in Helicobacter pylori eradication regimens. Vonoprazan may be combined with antibacterial agents as part of combination therapy. Its gastric acid suppression mechanism makes it relevant to pharmaceutical development involving H. pylori treatment.
During formulation development, pharmaceutical companies may evaluate Vonoprazan Fumarate for compatibility with excipients, dosage-form development, analytical testing, stability studies, dissolution performance, and manufacturing process development.
For pharmaceutical formulation development, the quality and physical characteristics of the API are important factors in determining formulation performance and manufacturing processes.
Depending on the intended dosage form and development stage, pharmaceutical companies may evaluate the following characteristics of Vonoprazan Fumarate:
The specific formulation strategy depends on the target product, dosage form, manufacturing process, regulatory requirements, and intended market.
Vonoprazan Fumarate CAS 1260141-27-2 can be evaluated as an API source for pharmaceutical companies involved in generic drug development and formulation research.
During generic drug development, pharmaceutical companies may conduct API evaluation, analytical testing, impurity assessment, formulation development, stability studies, and supplier qualification before moving toward pilot-scale or commercial production.
Typical API evaluation may include:
After laboratory and formulation evaluation, pharmaceutical manufacturers may require larger quantities of Vonoprazan Fumarate API for pilot-scale production, process validation, registration batches, and commercial manufacturing.
API requirements may vary according to the target dosage form, manufacturing process, annual demand, specification, regulatory requirements, packaging, and destination market.
Customers can provide their target specifications and project requirements for evaluation before placing an order.
Quality consistency is an important consideration when selecting a pharmaceutical API source. For Vonoprazan Fumarate, pharmaceutical customers may evaluate several quality attributes during supplier qualification and product development.
Assay and purity are fundamental quality attributes for pharmaceutical APIs. Appropriate analytical testing is used to confirm the identity and content of the active ingredient.
Related substances and potential degradation products are important considerations during API quality evaluation. The applicable limits should be determined according to the relevant specification and regulatory requirements.
Residual solvents may be evaluated as part of pharmaceutical API quality control. Customers may request relevant analytical or quality documentation according to their project requirements.
Elemental impurity risks may be evaluated according to applicable pharmaceutical quality and regulatory requirements. The assessment can form part of the supplier qualification process.
Consistent quality between production batches is important for formulation development, process validation, regulatory submissions, and commercial pharmaceutical manufacturing.
Technical documentation is an important part of API evaluation and supplier qualification. Depending on customer requirements and document availability, Xi’an Deli can provide relevant product and quality information for evaluation.
If your company has specific regulatory, quality, or registration requirements, please provide your document list for review.
Samples of Vonoprazan Fumarate CAS 1260141-27-2 can be discussed for laboratory evaluation, analytical testing, formulation development, and supplier qualification.
For a sample request, please provide the required sample quantity, destination country, company information, intended application, and any specific technical or quality requirements.
Appropriate packaging is important for protecting pharmaceutical APIs during storage and transportation. Packaging requirements may vary according to order quantity, transportation method, destination, and customer requirements.
For detailed information regarding packaging materials, available package sizes, storage conditions, and transportation requirements, please contact our team.
Xi’an Deli Biochemical Industry Co., Ltd. was established in 1999 and has more than 27 years of experience in the pharmaceutical and biochemical industry.
Our pharmaceutical portfolio includes APIs and excipients for international pharmaceutical customers. In addition to Vonoprazan Fumarate, our portfolio includes Glucosamine Sulfate Sodium Chloride, Hydroxypropyl Betadex (HPBCD), and Betadex Sulfobutyl Ether Sodium (SBECD).
Our experience in pharmaceutical ingredients allows us to communicate with customers regarding product specifications, technical documentation, samples, packaging, and commercial requirements throughout different stages of pharmaceutical development.
Vonoprazan Fumarate is the fumarate salt form of vonoprazan and belongs to the potassium-competitive acid blocker (P-CAB) class. It is used as an active pharmaceutical ingredient in pharmaceutical products involving gastric acid suppression.
The CAS number used for Vonoprazan Fumarate is 1260141-27-2. Another CAS identifier, 881681-01-2, is also associated with Vonoprazan Fumarate in public chemical databases. Customers should confirm the identifier required for their regulatory or purchasing documentation.
Vonoprazan Fumarate is used as an API in pharmaceutical products involving gastric acid suppression. Its pharmaceutical applications include acid-related gastrointestinal conditions and Helicobacter pylori eradication combination regimens.
Vonoprazan belongs to the potassium-competitive acid blocker (P-CAB) class.
Vonoprazan competitively inhibits potassium binding at the gastric H+/K+-ATPase proton pump, thereby suppressing gastric acid secretion.
The molecular formula of Vonoprazan Fumarate is C21H20FN3O6S.
The molecular weight of Vonoprazan Fumarate is approximately 461.46 g/mol.
Yes. Pharmaceutical companies can evaluate Vonoprazan Fumarate as an API source for formulation development, analytical evaluation, supplier qualification, and generic pharmaceutical development.
Yes. Samples can be discussed for laboratory testing, formulation development, analytical evaluation, and supplier qualification. Please provide the required sample quantity and destination for further arrangements.
Available documents may include Certificate of Analysis (COA), product specification, Safety Data Sheet (SDS), Technical Data Sheet (TDS), packaging information, and other technical or quality documents according to project requirements.
Please provide your required quantity, destination country, target specification, application, packaging requirements, and documentation requirements. Our team can review your requirements and provide product information and a quotation accordingly.
If your company is sourcing Vonoprazan Fumarate CAS 1260141-27-2 Pharmaceutical API for pharmaceutical development, formulation research, supplier qualification, or commercial manufacturing, Xi’an Deli Biochemical Industry Co., Ltd. welcomes your inquiry.
Please provide your required quantity, destination country, intended application, project stage, target specification, packaging requirements, and technical or regulatory documentation requirements.
Based on your requirements, we can provide available product information, technical documents, samples, packaging details, delivery information, and quotation support.
Contact Xi’an Deli Biochemical Industry Co., Ltd. to learn more about Vonoprazan Fumarate CAS 1260141-27-2 and our pharmaceutical API portfolio.
